ProMIS Files Management Information Circular in Connection with Annual General and Special Meeting of Shareholders
April 07 2022 - 7:00AM
ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF)
(“ProMIS” or the
“Corporation”), is
pleased to announce it has mailed the Notice of Notice-and-Access
(the “N&A Notice”) to shareholders of record of the Corporation
as of April 01, 2022, in connection with the Annual General and
Special Meeting of the Shareholders (the “Meeting”) of the
Corporation to be held Thursday, May 12, 2022, at 9:00 a.m.
(Pacific Time). In compliance with securities regulations, the
Corporation has also posted the N&A Notice together with the
combined Notice of Annual and Special Meeting of the Shareholders
and Management Proxy Circular, and the form of Proxy related to the
Meeting under the Corporation’s profile at www.sedar.com and on the
Corporation’s website at https://www.promisneurosciences.com/.
In consideration of the current coronavirus
COVID-19 pandemic (“COVID-19”), the Corporation
will hold the Meeting online via live virtual webcast at
https://meetnow.global/MZUVNJS.
YOUR VOTE IS IMPORTANT - PLEASE VOTE
TODAY
Meeting Matters
At the Meeting, Shareholders will be asked to
consider and vote on the following:
- ELECTION
OF DIRECTORS: To elect eight directors of the Corporation
for the ensuing year. See Election of Directors in the
Circular.
-
APPOINTMENT OF AUDITOR: To appoint the auditor of
the Corporation for the ensuing year and to authorize the directors
to fix the auditor’s remuneration. See Appointment of Auditor in
the Circular.
- AMENDMENT
OF BY-LAWS: To approve an ordinary
resolution to ratify, confirm and approve amendment by the Board of
Directors of the By-Laws of the Corporation to remove the Board’s
option to appoint alternate directors; and to change the definition
of quorum for a meeting of the Shareholders to increase quorum from
one-twentieth, being five (5%) percent, to thirty-three and
one-third (33 1/3%) percent of the issued Common Shares from time
to time. The purpose of the amendment is to bring the Corporation’s
governing constitution in line with the requirements of various
major North American exchanges. See Particulars of Matters to be
Acted upon – Amendment of By-Laws in the Management Proxy Circular
prepared for the Meeting and filed under the Corporation’s profile
at www.sedar.com and on the Corporation’s website at
https://www.promisneurosciences.com/.
The Board of Directors of ProMIS
recommends that Shareholders vote in favor of all
proposed items.
ProMIS encourages shareholders to read the
meeting material, which have been filed under the profile of ProMIS
at www.sedar.com and on the Corporation’s website at
https://www.promisneurosciences.com/.
Shareholder Information and
Questions
If you have questions or require assistance with
voting, please contact Laurel Hill Advisory Group,
the Corporation’s proxy solicitation and information agent:
Laurel Hill Advisory GroupNorth American
Toll-Free Number: 1-877-452-7184Calls Outside North America:
416-304-0211Email: assistance@laurelhill.com
About ProMIS Neurosciences
Inc.
ProMIS Neurosciences Inc. is a development stage
biotechnology corporation focused on discovering and developing
antibody therapeutics selectively targeting toxic oligomers
implicated in the development and progression of neurodegenerative
diseases, in particular Alzheimer’s disease (AD), amyotrophic
lateral sclerosis (ALS) and Multiple system atrophy (MSA). The
Corporation’s proprietary target discovery engine is based on the
use of two complementary techniques. The Corporation applies its
thermodynamic, computational discovery platform - ProMIS™ and
Collective Coordinates - to predict novel targets known as Disease
Specific Epitopes on the molecular surface of misfolded proteins.
Using this unique approach, the Corporation is developing novel
antibody therapeutics for AD, ALS and MSA. ProMIS is headquartered
in Toronto, Ontario, Canada with offices in Cambridge,
Massachusetts, U.S.A. ProMIS is listed on the Toronto Stock
Exchange (“TSX”) under symbol PMN, and on the OTCQB Venture Market
under symbol ARFXF.
Visit us at
www.promisneurosciences.com, follow us
on Twitter and
LinkedIn
For Investor Relations please contact:Alpine Equity
AdvisorsNicholas Rigopulos, Presidentnick@alpineequityadv.comTel.
617 901-0785
The TSX has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.
Certain information in this news release constitutes
forward-looking statements and forward-looking information
(collectively, "forward-looking information") within the meaning
of applicable securities laws. In some cases, but not necessarily
in all cases, forward-looking information can be identified by the
use of forward-looking terminology such as "plans", "targets",
"expects" or "does not expect", "is expected", "an opportunity
exists", "is positioned", "estimates", "intends", "assumes",
"anticipates" or "does not anticipate" or "believes", or variations
of such words and phrases or state that certain actions, events or
results "may", "could", "would", "might", "will" or "will be
taken", "occur" or "be achieved". In addition, any statements that
refer to expectations, projections or other characterizations of
future events or circumstances contain forward-looking
information. Specifically, this news release contains
forward-looking information relating to future management and Board
composition of the Corporation and the potential benefits of
targeting misfolded proteins. Statements containing forward-looking
information are not historical facts but instead represent
management's current expectations, estimates and projections
regarding the future of our business, future plans, strategies,
projections, anticipated events and trends, the economy and other
future conditions. Forward-looking information is necessarily based
on a number of opinions, assumptions and estimates that, while
considered reasonable by the Corporation as of the date of this
news release, are subject to known and unknown risks,
uncertainties, assumptions and other factors that may cause the
actual results, level of activity, performance or achievements to
be materially different from those expressed or implied by such
forward-looking information. Important factors that could cause
actual results and financial condition to differ materially from
those indicated in the forward-looking information include, among
others, the factors discussed throughout the "Risk Factors" section
of the Corporation's most recently filed annual information form
available on www.SEDAR.com. Additionally, notwithstanding whether
the amendment to change the quorum requirement is approved by
shareholders or otherwise, there is no assurance that the company
will meet the quantitative or qualitative requirements to list on a
major North American stock exchange. Except as required by
applicable securities laws, the Corporation undertakes no
obligation to publicly update any forward-looking information,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.
ProMIS Neurosciences (TSX:PMN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ProMIS Neurosciences (TSX:PMN)
Historical Stock Chart
From Jul 2023 to Jul 2024